Education
About Us
Working with TipRanks
Follow Us
Fresh Tracks Therapeutics, Inc. (FRTX)
OTHER OTC:FRTX
Total Valuation
Fresh Tracks Therapeutics has a market cap or net worth of $5.59M. The enterprise value is ―.
Market Cap$5.59M
Enterprise Value―
Share Statistics
Fresh Tracks Therapeutics has 7,811,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,811,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Fresh Tracks Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee2.00M
Profits Per Employee-1.42M
Employee Count4
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Fresh Tracks Therapeutics is ―. Fresh Tracks Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.70
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Fresh Tracks Therapeutics had revenue of 8.01M and earned -5.69M in profits. Earnings per share was -0.96.
Revenue8.01M
Gross Profit8.01M
Operating Income-6.36M
Pretax Income-5.69M
Net Income-5.69M
EBITDA-5.65M
Earnings Per Share (EPS)-0.96
Cash Flow
In the last 12 months, operating cash flow was -4.34M and capital expenditures 0.00, giving a free cash flow of -4.34M billion.
Operating Cash Flow-4.34M
Free Cash Flow-4.34M
Free Cash Flow per Share-0.56
Dividends & Yields
Fresh Tracks Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.19
52-Week Price Change4.44%
50-Day Moving Average0.82
200-Day Moving Average0.82
Relative Strength Index (RSI)79.31
Average Volume (3m)2.67K
Important Dates
Fresh Tracks Therapeutics upcoming earnings date is Aug 8, 2024, TBA Not Confirmed.
Last Earnings DateMay 9, 2024
Next Earnings DateAug 8, 2024
Ex-Dividend Date―
Financial Position
Fresh Tracks Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Fresh Tracks Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
Fresh Tracks Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Fresh Tracks Therapeutics has $10.87M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$10.87M billion.
Cash & Marketable Securities$10.87M
Total Debt$0.00
Net Cash-$10.87M
Net Cash Per Share-$1.39
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Fresh Tracks Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―